Alzamend Neuro to Present Clinical Trial Progress at Sequire Investor Summit
核心洞察
Alzamend Neuro will present at the Sequire Investor Summit on January 22, 2025, to update on clinical trial progress.
CEO Stephan Jackman will highlight the company's improved financial position and AL001's Phase II trials.
Five Phase II trials for AL001, in partnership with Massachusetts General Hospital, are set to begin in 2025.
Alzamend Neuro, Inc. (Nasdaq: ALZN) will present at the Sequire Investor Summit in Puerto Rico from January 21-23, 2025, providing an update on its clinical trial progress and expected milestones. Stephan Jackman, Alzamend’s Chief Executive Officer, is scheduled to present on January 22, 2025, at 11:30 a.m. ET.
Jackman is expected to highlight the company's improved financial standing over the past year and discuss the positioning of AL001 for five Phase II trials slated to commence in 2025. These trials will be conducted in partnership with Massachusetts General Hospital.
Alzamend Neuro is a clinical-stage biopharmaceutical company focused on developing novel treatments for a range of psychiatric and neurodegenerative diseases. Their pipeline includes two drug candidates: AL001, an ionic cocrystal technology for delivering lithium, and ALZN002, a cell-based therapeutic vaccine targeting Alzheimer’s disease (搜索).
AL001 utilizes a patented technology combining lithium, salicylate, and L-proline. Alzamend believes this novel formulation can improve the therapeutic profile of lithium. ALZN002 employs a mutant-peptide sensitized cell approach to stimulate the patient's immune system to combat Alzheimer's.
The Sequire Investor Summit is expected to host over 75 presenting companies and 500 investors, funds, family offices, and analysts. The summit offers a platform for companies like Alzamend to connect with potential investors and share updates on their progress.